Armata Pharmaceuticals Inc
$ 4.70
0.43%
05 Aug - close price
- Market Cap 171,807,000 USD
- Current Price $ 4.70
- High / Low $ 4.75 / 4.51
- Stock P/E N/A
- Book Value -8.50
- EPS -7.21
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -34.39 %
- 52 Week High 14.98
- 52 Week Low 2.36
About
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant infections worldwide. The company is headquartered in Marina del Rey, California.
Analyst Target Price
$17.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-25 | 2025-11-12 | 2025-08-12 | 2025-05-14 | 2025-03-20 | 2024-11-13 | 2024-08-13 | 2024-05-07 | 2024-03-21 | 2023-11-14 | 2023-08-14 |
| Reported EPS | -3.16 | -0.5112 | -0.33 | -0.29 | -0.2 | -0.2317 | -0.15 | -0.4 | -0.33 | -0.55 | -0.32 | -0.27 |
| Estimated EPS | -0.38 | -0.19 | -0.42 | -0.39 | -0.38 | -0.35 | -0.28 | -0.36 | -0.31 | -0.35 | -0.31 | -0.37 |
| Surprise | -2.78 | -0.3212 | 0.09 | 0.1 | 0.18 | 0.1183 | 0.13 | -0.04 | -0.02 | -0.2 | -0.01 | 0.1 |
| Surprise Percentage | -731.5789% | -169.0526% | 21.4286% | 25.641% | 47.3684% | 33.8% | 46.4286% | -11.1111% | -6.4516% | -57.1429% | -3.2258% | 27.027% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.48 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARMP
2026-08-01 08:11:55
This article provides an overview of Armata Pharmaceuticals, Inc. (AMEX:ARMP) stock performance, financial estimates, and key metrics. It includes information on current stock price, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnings reports. The content also addresses frequently asked questions regarding the company's stock.
2026-07-30 05:41:19
Armata Pharmaceuticals Inc (ARMP) currently has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 9.14%, a significant quarter-over-quarter increase of 320.60%. Noteworthy institutional investors include Innoviva Inc, 683 Capital Management LLC, and Geode Capital Management, L.L.C., with James Simons identified as the largest institutional shareholder by percentage of shares outstanding, holding 0.11% with a 4.86% increase.
2026-07-28 04:12:44
This article provides a detailed financial overview of Armata Pharmaceuticals Inc. (ARMP), highlighting its latest reported earnings, revenue, and financial statements. It includes quarterly and annual data for EPS, revenue, net profit, balance sheet items like current assets, total assets, current liabilities, total liabilities, and total equity, as well as cash flow statement items. The report also includes FAQs deriving key financial figures directly from the FY2025 earnings report.
2026-07-27 07:11:48
This article provides an in-depth look at Armata Pharmaceuticals Inc (ARMP)'s cash flow statement, covering quarterly and annual data. It details operating, investing, and financing cash flows, along with essential financial metrics like net income, capital expenditures, and free cash flow. The piece also includes an FAQ section explaining key cash flow concepts and their relevance to ARMP's financial health.
2026-07-25 09:40:43
This article details the shareholder structure of Armata Pharmaceuticals Inc (ARMP), highlighting major shareholders and institutional holdings. Innoviva Inc. is the largest shareholder, holding 68.34% of the shares, followed by Madison Asset Management LLC and Vanguard Capital Management, LLC. The report also breaks down institutional shareholding trends over recent quarters and lists significant shareholder activities.
2026-07-25 05:40:43
Armata Pharmaceuticals Inc. (ARMP) is a clinical-stage biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant infections. The company's stock currently trades at $4.66, with analysts rating it as a "Buy" and a target price of $17.50. Despite weak fundamentals and recent market performance, the company shows significant growth potential and strong technicals, although the stock price is expected to trend down in the medium term.
